Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05311176
Title A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) (nextHERIZON)
Acronym nextHERIZON
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Imugene Limited
Age Groups: adult | senior
Covered Countries AUS

No variant requirements are available.